Concepedia

Lucy C. Riches

LC

Statistics

Publications

4

Citations

556

H-Index

4

Active since

2018

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (United States)

Virginia Commonwealth University

Lucy C. Riches is an author at AstraZeneca (United Kingdom) specializing in oncology, medicine, and dna damage response inhibitors.

Publications per year

2018–2019

4

Publications

4

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Stephen T. Durant, Li Zheng, Yingchun Wang et al. · Science Advances · 2018 · 312 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2019 · 160 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Jeremy Karlin, Jasmine Allen, Syed Farhan Ahmad et al. · Molecular Cancer Therapeutics · 2018 · 61 citations · Full text

Medicine, Oncology, Pharmacology +16

Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles

Elisabetta Leo, Jeffrey W. Johannes, Giuditta Illuzzi et al. · Cancer Research · 2018 · 23 citations

Medicine, Oncology, Pharmacology +16

1–4 of 4